[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Article](https://github.com/mm80843/T3.5/tree/pages/docs/Article/index.md) >> Individual ID:PBN__Article_608 

# __Pilz_contributions_2022__

## List of risks in an article

* [Accumulating evidence on the efficacy and duration of natural immunity contributing to the mitigation of the covid-19 pandemic](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16345.md)
* [Incomplete vaccination data due to vaccinations taking place outside of the health system](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16346.md)
* [Lower testing frequency in previously sars-cov-2 infected participants versus the control group](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16347.md)
* [Seroprevalence surveys suggesting higher infection rates than reported sars-cov-2 cases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16348.md)
* [Unclear efficacy of protection against re-infections in people with and without symptoms at their initial sars-cov-2 infection](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16349.md)

## This article mentions these technologies

* [Data analysis software](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_552.md)
* [Data analysis tools](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1814.md)
* [Data completion tools](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1532.md)
* [Preventive and therapeutic measures](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_826.md)
* [Research studies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_265.md)
* [Serological testing](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_18732.md)
* [Testing protocols](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_18733.md)
* [Vaccines](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_18734.md)

